A Response to: "Letter to the Editor Regarding 'Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis'".

Saved in:
Bibliographic Details
Title: A Response to: "Letter to the Editor Regarding 'Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis'".
Authors: Augustin M; Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. m.augustin@uke.de., Armstrong AW; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Issa NT; Forefront Dermatology, Vienna, VA, USA.; Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.; George Washington University School of Medicine and Health Sciences, Washington, DC, USA., Petersen AS; LEO Pharma A/S, Ballerup, Denmark., von Eyben R; LEO Pharma A/S, Ballerup, Denmark., Festini T; LEO Pharma A/S, Ballerup, Denmark., Torres T; Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal.; Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Source: Dermatology and therapy [Dermatol Ther (Heidelb)] 2026 Jun 26. Date of Electronic Publication: 2026 Jun 26.
Publication Type: Letter
Journal Info: Publisher: Springer Healthcare Communications Country of Publication: Switzerland NLM ID: 101590450 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8210 (Print) NLM ISO Abbreviation: Dermatol Ther (Heidelb)
Database: MEDLINE Ultimate
Description
ISSN:2193-8210
DOI:10.1007/s13555-026-01798-8